Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Oregon Health & Science University

Headquarters: Portland, OR, United States of America
Year Founded: 1974
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Feb 26, 2025
Distillery Therapeutics

Targeting CD74 for familial platelet disorder

BioCentury | Jan 27, 2025
Discovery & Translation

Science Spotlight: Improving safety of live-attenuated vaccines

BioCentury’s roundup of translational innovations also includes base editing for prion disease, a Flagship collab, and six papers with links to newcos
BioCentury | Jan 23, 2024
Politics, Policy & Law

How Arnold Ventures paved the road to the IRA

And what the biopharma industry’s most effective critic wants to do next
BioCentury | Nov 16, 2023
Discovery & Translation

Aldena’s JAK-1-selective siRNA; an aerosol mAb for SARS-CoV-2 and more

BioCentury’s roundup of translational innovations
BioCentury | Aug 4, 2023
Discovery & Translation

Altering CAR surface availability; plus Allogene’s CAR T cells and more

BioCentury’s roundup of translational innovations
BioCentury | Dec 8, 2022
Discovery & Translation

A mosaic nanoparticle vaccine for HCV; plus mitochondrial zinc finger base editors and more

BioCentury’s roundup of translational news
BioCentury | Oct 4, 2022
Distillery Therapeutics

RNA editing of MECP2 for Rett syndrome

BioCentury | May 17, 2022
Management Tracks

CRISPR, Nkarta join flurry of CMO moves

Siegall leaving Seagen amid concerns over conduct; new CFO at Mirati and more
BioCentury | Apr 1, 2022
Discovery & Translation

An in vivo CAR T manufacturing implant; plus Seer, Kither and more

BioCentury’s roundup of translational news
BioCentury | Dec 9, 2021
Management Tracks

Wilson joins gene therapy play Rocket

Plus updates from Tessera, Oramed, Ikena and more
Items per page:
1 - 10 of 219